How to revive breakthrough innovation in the pharmaceutical industry

Science Translational Medicine

Volumn 3, Issue 89, 2011, Pages

  Munos, Bernard H ^a   Chin, William W ^b  

^a InnoThink Center for Research in Biomedical Innovation   (United States)

^b HARVARD MEDICAL SCHOOL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CLINICAL PHARMACY; CLINICAL PRACTICE; COST CONTROL; DRUG INDUSTRY; DRUG MARKETING; DRUG RESEARCH; DRUG SAFETY; DRUG SCREENING; ECONOMIC DEVELOPMENT; HUMAN; INVESTMENT; LEADERSHIP; MEDICAL TECHNOLOGY; NOTE; ORGANIZATIONAL DEVELOPMENT; PREDICTION; PRIORITY JOURNAL; PUBLIC-PRIVATE PARTNERSHIP; RISK ASSESSMENT; RISK MANAGEMENT; TRANSLATIONAL RESEARCH; ARTICLE; DRUG DEVELOPMENT; ECONOMICS; ORGANIZATION AND MANAGEMENT; RESEARCH; RISK FACTOR;

DRUG;

DRUG DISCOVERY; DRUG INDUSTRY; HUMANS; PHARMACEUTICAL PREPARATIONS; RESEARCH; RISK FACTORS;

EID: 79959786193     PISSN: 19466234     EISSN: 19466242     Source Type: Journal    
DOI: 10.1126/scitranslmed.3002273     Document Type: Note

References (28)

1. E. Arias, United States Life Tables, 2006. National Vital Statistics Report Volume 58 (28 June 2010). http://www.cdc.gov/nchs/data/nvsr/nvsr58/ nvsr58-21.pdf.
2. Data available at www.fda.gov/downloads/AboutFDA/Transparency/Basics/ UCM247465.pdf.
3. R. Evans, S. Hinds, D. Hammock, Portfolio analysis and R&D decision making. Nat. Rev. Drug Discov. 8, 189-190 (2009).
4. F. M. Scherer, Markets and Uncertainty in Pharmaceutical Development, Working Paper RWP07-039, Harvard University, September 2007. http://web.hks.harvard.edu/publications/getFile.aspx?Id=267.
5. Aranesp (darbepoetin alpha, Amgen), Neulasta (pegfilgrastim, Amgen), Zocor (simvastatin, Merck & Co), Eloxatin (oxaliplatin, Sanofi), PegIntron (peginterferon alpha- 2b, Merck & Co), Humalog (recombinant insulin lispro, Eli Lilly), Augmentin (amoxicillin + clavulanate potassium, GlaxoSmithKline).
6. B. Munos, How to avert biopharma's R&D crisis. In Vivo (1 March 2011). http://sis.windhover.com/buy/abstract.php?id=2011800050&utm-source= rss.
7. F. Pammolli, L. Magazzini, M. Riccaboni, The productivity crisis of pharmaceutical R&D. Nat. Rev. Drug Discov. 10, 428-438 (2011).
8. M. Riccaboni, R. Moliterni, Managing technological transitions through R&D alliances. R & D Manag. 39, 124-135 (2009).
9. This figure breaks down into about $95 billion for the top 20 pharmas (annual reports, JP Morgan), $35 billion for small pharma and biotech companies (Burrill & Company), and $31 billion for NIH (www.nih.gov/about/budget.htm).
10. N. Behnke, N. Hueltenschmidt, Changing pharma's innovation DNA. Bain & Company (13 August 2010). http://www.bain.com/bainweb/Publications/ article-detail.asp?id=27923&menu-url=articles.asp&origin= bainweb-homepage&origin=bainweb-homepage.
11. J. Arrowsmith, Trial watch: Phase III and submission failures: 2007-2010. Nat. Rev. Drug Discov. 10, 87 (2011).
12. H. G. Eichler, quoted in M. Gordian, N. Singh, R. Zemmel, T. Elias, Why products fail in phase III. In Vivo (1 April 2006). http://sis.windhover.com/ buy/abstract.php?id=2006800066. Eichler is the Senior Medical Officer at the European Medicines Agency.
13. Data from www.clinicaltrials.gov show big pharma routinely sponsors dozens of phase III trials (as many as 60 in some cases) to support its best-selling drugs.
14. J. Carroll, UK pharma czar sees new "innovation ecosystem" R&D model emerge. FierceBiotech (2 June 2011). http://www.fiercebiotech.com/ story/uk-pharma-czar-seesnew-innovation-ecosystem-rd-model-emerge/2011-06-02? utm-medium=nl&utm-source=internal.
15. F. J. Cohen, Macro trends in pharmaceutical innovation. Nat. Rev. Drug Discov. 4, 78-84 (2005).
16. E. Bonabeau, N. Bodick, R. W. Armstrong, A more rational approach to new-product development. Harvard Business Review (March 2008).
17. Eli Lilly PD2, https://pd2.lilly.com/pd2Web.
18. T. Norman, A. Edwards, C. Bountra, S. Friend, The precompetitive space: Time to move the yardsticks. Sci. Transl. Med. 3, 76cm10 (2011).
19. T. C. Norman, C. Bountra, A. M. Edwards, K. R. Yamamoto, S. H. Friend, Leveraging crowdsourcing to facilitate the discovery of new medicines. Sci. Transl. Med. 3, 88mr1 (2011).
20. S. N. Strauss, Open access consortium. Nat. Biotechnol. 29, 298 (2011).
21. B. Munos, Lessons from 60 years of pharmaceutical innovation. Nat. Rev. Drug Discov. 8, 959-968 (2009).
22. This is because the highly skewed distribution of drug sales grossly violates the normality assumption that underpins the model and invalidates it. Under such conditions, the law of large numbers - in which the model is grounded - breaks down. Some degree of risk mitigation can be achieved by portfolio management but far too little to be an effective tool. For a mathematical treatment of blockbuster economics, see (27).
23. F. M. Scherer, D. Harhoff, Technology policy for a world of skew-distributed outcomes. Res. Policy 29, 559-566 (2000).
24. A. Witty, Research and Develop, The Economist (22 November 2010). http://www.economist.com/node/17493432.
25. A. Jack, Eli Lilly funds aim to share research costs. Financial Times (13 February 2011). http://www.ft.com/cms/s/0/4a7f55aa-379f-11e0-b91a-00144feabdc0. html#axzz1PvdMQZIA.
26. B. H. Munos, W. W. Chin, A call for sharing: Adapting pharmaceutical research to new realities. Sci. Transl. Med. 1, 9cm8 (2009).
27. A. De Vany, Hollywood Economics: How Extreme Uncertainty Shapes the Film Industry (Routledge, Oxford, 2003).
28. Competing interests: The authors are recent former employees of Eli Lilly